Rob, some years ago you would have had trouble selecting IDX from the crowd that included FINX, DBII, NRID, and AFIS. Since then we've seen the arrival of SACM, DDSI, and GDER. Probably I've left one out.
The others are nowhere in bio-ID. In fact, I am having a hard time coming up with a credible competitor to IDX right now. As someone suggested to me, CTST was remarkable for its lack of competing products . . . because IDX's success is cutting off the wannabes' access to more venture capital.
The difference has to be Fowler. IDX does not seem to have a genius lab guy coming up with breakthrough products every year. Fowler has just had a better sense of where to go with this company than any of his rivals, and if he missing a piece, he buys it with stock.
If you are bullish on IDX, it's because Fowler has put the company in this favorable position. It might make you feel better if you realize that Scullion has been promoted, IDT retains a great deal of autonomy under prior management, and IDX has just recruited a new VP from RSI.
Is it personal between you and Fowler? |
